Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||GSK2334470 + Idelalisib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GSK2334470||GSK-470||PDPK1 Inhibitor 10||GSK2334470 is a small molecule inhibitor of PDPK1, which subsequently results in suppression of Akt and may result in antiproliferative activity (PMID: 29658600, PMID: 32188393).|
|Idelalisib||Zydelig||CAL-101|GS-1101||PIK3CD inhibitor 26||Zydelig (idelalisib) inhibits PI3K-delta, preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival (PMID: 24450857). Zydelig (idelalisib) is FDA approved for follicular B-cell non-Hodgkin lymphoma, relapsed small lymphocytic lymphoma, and in combination with Rituxan (rituximab) for relapsed chronic lymphocytic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTEN loss||diffuse large B-cell lymphoma||predicted - sensitive||GSK2334470 + Idelalisib||Preclinical - Cell culture||Actionable||In a preclinical study, GSK2334470 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss that acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).||28178345|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|